Target Price | $15.30 |
Price | $7.08 |
Potential |
116.10%
register free of charge
|
Number of Estimates | 7 |
7 Analysts have issued a price target Karyopharm Therapeutics, Inc. 2026 .
The average Karyopharm Therapeutics, Inc. target price is $15.30.
This is
116.10%
register free of charge
$31.50
344.92%
register free of charge
$8.08
14.12%
register free of charge
|
|
A rating was issued by 13 analysts: 10 Analysts recommend Karyopharm Therapeutics, Inc. to buy, 3 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Karyopharm Therapeutics, Inc. stock has an average upside potential 2026 of
116.10%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 145.24 | 150.56 |
0.54% | 3.66% | |
EBITDA Margin | -82.00% | -88.07% |
7.18% | 7.40% | |
Net Margin | -52.62% | -64.00% |
46.31% | 21.64% |
9 Analysts have issued a sales forecast Karyopharm Therapeutics, Inc. 2025 . The average Karyopharm Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Karyopharm Therapeutics, Inc. EBITDA forecast 2025. The average Karyopharm Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $-119m | 7.68% |
---|---|---|
2025 |
$-133m
11.34%
Unlock
|
2024 | -82.00% | 7.18% |
---|---|---|
2025 |
-88.07%
7.40%
Unlock
|
9 Karyopharm Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Karyopharm Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -9.41 | -11.14 |
49.92% | 18.38% | |
P/E | negative | |
EV/Sales | 1.75 |
9 Analysts have issued a Karyopharm Therapeutics, Inc. forecast for earnings per share. The average Karyopharm Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Karyopharm Therapeutics, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
Baird |
Locked
➜
Locked
|
Locked | Aug 12 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jul 16 2025 |
Baird |
Locked
➜
Locked
|
Locked | May 13 2025 |
Barclays |
Locked
➜
Locked
|
Locked | May 13 2025 |
RBC Capital |
Locked
➜
Locked
|
Locked | May 13 2025 |
Baird |
Locked
➜
Locked
|
Locked | Mar 03 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 26 2025 |
Analyst Rating | Date |
---|---|
Locked
Baird:
Locked
➜
Locked
|
Aug 12 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jul 16 2025 |
Locked
Baird:
Locked
➜
Locked
|
May 13 2025 |
Locked
Barclays:
Locked
➜
Locked
|
May 13 2025 |
Locked
RBC Capital:
Locked
➜
Locked
|
May 13 2025 |
Locked
Baird:
Locked
➜
Locked
|
Mar 03 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 26 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.